Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.37
PRXL's Cash to Debt is ranked lower than
77% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.62 vs. PRXL: 0.37 )
Ranked among companies with meaningful Cash to Debt only.
PRXL' s Cash to Debt Range Over the Past 10 Years
Min: 0.17  Med: 13.63 Max: No Debt
Current: 0.37
Equity to Asset 0.29
PRXL's Equity to Asset is ranked lower than
82% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. PRXL: 0.29 )
Ranked among companies with meaningful Equity to Asset only.
PRXL' s Equity to Asset Range Over the Past 10 Years
Min: 0.27  Med: 0.46 Max: 0.72
Current: 0.29
0.27
0.72
Interest Coverage 26.16
PRXL's Interest Coverage is ranked lower than
52% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.61 vs. PRXL: 26.16 )
Ranked among companies with meaningful Interest Coverage only.
PRXL' s Interest Coverage Range Over the Past 10 Years
Min: 3.16  Med: 5.52 Max: 28.51
Current: 26.16
3.16
28.51
F-Score: 5
Z-Score: 3.58
M-Score: -2.71
WACC vs ROIC
4.76%
18.46%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 8.27
PRXL's Operating margin (%) is ranked higher than
63% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.72 vs. PRXL: 8.27 )
Ranked among companies with meaningful Operating margin (%) only.
PRXL' s Operating margin (%) Range Over the Past 10 Years
Min: 5.24  Med: 6.25 Max: 8.8
Current: 8.27
5.24
8.8
Net-margin (%) 6.09
PRXL's Net-margin (%) is ranked higher than
66% of the 192 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.29 vs. PRXL: 6.09 )
Ranked among companies with meaningful Net-margin (%) only.
PRXL' s Net-margin (%) Range Over the Past 10 Years
Min: 3.1  Med: 3.98 Max: 6.34
Current: 6.09
3.1
6.34
ROE (%) 25.52
PRXL's ROE (%) is ranked higher than
95% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.60 vs. PRXL: 25.52 )
Ranked among companies with meaningful ROE (%) only.
PRXL' s ROE (%) Range Over the Past 10 Years
Min: 9.33  Med: 11.97 Max: 23.79
Current: 25.52
9.33
23.79
ROA (%) 7.79
PRXL's ROA (%) is ranked higher than
81% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.53 vs. PRXL: 7.79 )
Ranked among companies with meaningful ROA (%) only.
PRXL' s ROA (%) Range Over the Past 10 Years
Min: 3.4  Med: 5.22 Max: 7.99
Current: 7.79
3.4
7.99
ROC (Joel Greenblatt) (%) 46.50
PRXL's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -12.38 vs. PRXL: 46.50 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
PRXL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 21.14  Med: 41.72 Max: 58.04
Current: 46.5
21.14
58.04
Revenue Growth (3Y)(%) 15.90
PRXL's Revenue Growth (3Y)(%) is ranked higher than
82% of the 134 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.10 vs. PRXL: 15.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
PRXL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 5.3  Med: 13.90 Max: 28.8
Current: 15.9
5.3
28.8
EBITDA Growth (3Y)(%) 24.90
PRXL's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 114 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. PRXL: 24.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
PRXL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -11.4  Med: 15.70 Max: 56.4
Current: 24.9
-11.4
56.4
EPS Growth (3Y)(%) 36.30
PRXL's EPS Growth (3Y)(%) is ranked higher than
91% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. PRXL: 36.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
PRXL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -27.4  Med: 22.20 Max: 40.2
Current: 36.3
-27.4
40.2
» PRXL's 10-Y Financials

Financials (Next Earnings Date: 2016-08-03)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

PRXL Guru Trades in Q2 2015

Steven Cohen 409,200 sh (New)
Jim Simons 708,800 sh (+14.07%)
Vanguard Health Care Fund 3,790,200 sh (unchged)
Ken Fisher 2,431,850 sh (-0.32%)
Chuck Royce 337,400 sh (-12.39%)
Joel Greenblatt 918,656 sh (-27.44%)
» More
Q3 2015

PRXL Guru Trades in Q3 2015

Steven Cohen Sold Out
Ken Fisher 2,393,327 sh (-1.58%)
Chuck Royce 326,400 sh (-3.26%)
Vanguard Health Care Fund 3,446,741 sh (-9.06%)
Jim Simons 601,900 sh (-15.08%)
Joel Greenblatt 711,727 sh (-22.53%)
» More
Q4 2015

PRXL Guru Trades in Q4 2015

George Soros 5,800 sh (New)
Ken Fisher 2,355,456 sh (-1.58%)
Chuck Royce 313,300 sh (-4.01%)
Jim Simons 371,000 sh (-38.36%)
Vanguard Health Care Fund 2,015,640 sh (-41.52%)
Joel Greenblatt 316,310 sh (-55.56%)
» More
Q1 2016

PRXL Guru Trades in Q1 2016

Steven Cohen 69,900 sh (New)
Paul Tudor Jones 8,000 sh (New)
George Soros Sold Out
Joel Greenblatt Sold Out
Ken Fisher 2,336,981 sh (-0.78%)
Chuck Royce 300,800 sh (-3.99%)
Vanguard Health Care Fund 1,836,340 sh (-8.90%)
Jim Simons 146,700 sh (-60.46%)
» More
» Details

Insider Trades

Latest Guru Trades with PRXL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:OTCPK:SWTUY, OTCPK:DSRLF, NAS:BRKR, NAS:ICLR, OTCPK:CZMWY, NAS:VWR, NYSE:CRL, NYSE:BIO, NAS:PRAH, NAS:CPHD, NAS:INCR, NAS:MYGN, NAS:NEOG, OTCPK:BMXMF, NAS:QGEN, NAS:KANG, NAS:EXAS, NAS:AFFX, OTCPK:ERFSF, NAS:AXDX » details
Traded in other countries:PAX.Germany,
Parexel International Corp is a biopharmaceutical services company. The Company offers clinical research, clinical logistics, medical communications, and technology products and services to the pharmaceutical, biotechnology, and medical device industries.

Parexel International Corp was incorporated in 1983. The Company provides clinical research, medical communications, consulting, commercialization and informatics and technology services to the pharmaceutical, biotechnology, and medical device industries. The Company has three reporting segments: Clinical Research Services (CRS), PAREXEL Consulting and Medical Communications Services (PCMS), and Perceptive Informatics (Perceptive). CRS constitutes its core business and include all phases of clinical research from first-in-man trials, where a medicinal entity is tested on human subjects for the first time, through post-marketing studies, following approval by the presiding regulatory body. CRS service offerings include clinical trials management, observational studies, patient/disease registries and post-marketing surveillance, data management and biostatistics, epidemiology and health economics/outcomes research, clinical logistics, pharmacovigilance, and clinical pharmacology, as well as related medical affairs, patient recruitment, and investigator site services. PCMS provides technical expertise and advice in such areas as drug development, regulatory affairs, and good manufacturing practice (GMP) compliance consulting. In addition, PCMS provides a full spectrum of market development, product development, commercialization, and targeted communications services in support of product launch. PCMS consultants also identify alternatives and propose solutions to address clients' product development, registration, and commercialization issues. Additionally, PCMS provides reimbursement and market access (RMA) services. Perceptive provides information technology solutions designed to improve clients' product development processes. Perceptive's portfolio of products and services includes ClinPhone RTSM, medical imaging services, CTMS, EDC, web-based portals, systems integration, and patient diary applications. These solutions are sold individually or in combination, as elements of an eClinical suite. It competes with other biopharmaceutical services companies and other clinical research organizations (CROs) that provide one or more of the services being offered by it. Some of the biopharmaceutical services companies, such as Quintiles Transnational Corporation, Covance Inc., Pharmaceutical Product Development Inc., inVentiv Health, INC Research, and Icon plc, offer services that compete directly with its services at many levels.

Ratios

vs
industry
vs
history
P/E(ttm) 24.94
PRXL's P/E(ttm) is ranked higher than
63% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 34.11 vs. PRXL: 24.94 )
Ranked among companies with meaningful P/E(ttm) only.
PRXL' s P/E(ttm) Range Over the Past 10 Years
Min: 6.48  Med: 26.45 Max: 42.24
Current: 24.94
6.48
42.24
Forward P/E 16.69
PRXL's Forward P/E is ranked higher than
86% of the 36 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.76 vs. PRXL: 16.69 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 24.94
PRXL's PE(NRI) is ranked higher than
63% of the 99 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.79 vs. PRXL: 24.94 )
Ranked among companies with meaningful PE(NRI) only.
PRXL' s PE(NRI) Range Over the Past 10 Years
Min: 6.5  Med: 26.55 Max: 42.45
Current: 24.94
6.5
42.45
Price/Owner Earnings (ttm) 39.54
PRXL's Price/Owner Earnings (ttm) is ranked lower than
60% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 33.58 vs. PRXL: 39.54 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
PRXL' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.66  Med: 26.14 Max: 475.93
Current: 39.54
9.66
475.93
P/B 5.88
PRXL's P/B is ranked lower than
75% of the 208 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.37 vs. PRXL: 5.88 )
Ranked among companies with meaningful P/B only.
PRXL' s P/B Range Over the Past 10 Years
Min: 0.98  Med: 3.23 Max: 8
Current: 5.88
0.98
8
P/S 1.49
PRXL's P/S is ranked higher than
77% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.37 vs. PRXL: 1.49 )
Ranked among companies with meaningful P/S only.
PRXL' s P/S Range Over the Past 10 Years
Min: 0.33  Med: 1.11 Max: 1.77
Current: 1.49
0.33
1.77
PFCF 47.13
PRXL's PFCF is ranked lower than
75% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.85 vs. PRXL: 47.13 )
Ranked among companies with meaningful PFCF only.
PRXL' s PFCF Range Over the Past 10 Years
Min: 9.42  Med: 22.74 Max: 3775
Current: 47.13
9.42
3775
POCF 19.40
PRXL's POCF is ranked lower than
51% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.37 vs. PRXL: 19.40 )
Ranked among companies with meaningful POCF only.
PRXL' s POCF Range Over the Past 10 Years
Min: 5.13  Med: 16.03 Max: 2776
Current: 19.4
5.13
2776
EV-to-EBIT 19.58
PRXL's EV-to-EBIT is ranked higher than
50% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.96 vs. PRXL: 19.58 )
Ranked among companies with meaningful EV-to-EBIT only.
PRXL' s EV-to-EBIT Range Over the Past 10 Years
Min: 5.9  Med: 17.60 Max: 272.6
Current: 19.58
5.9
272.6
EV-to-EBITDA 13.24
PRXL's EV-to-EBITDA is ranked higher than
57% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.01 vs. PRXL: 13.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
PRXL' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 11.20 Max: 19.5
Current: 13.24
4.3
19.5
PEG 1.22
PRXL's PEG is ranked higher than
79% of the 38 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. PRXL: 1.22 )
Ranked among companies with meaningful PEG only.
PRXL' s PEG Range Over the Past 10 Years
Min: 0.24  Med: 1.53 Max: 15.4
Current: 1.22
0.24
15.4
Shiller P/E 45.99
PRXL's Shiller P/E is ranked lower than
53% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 43.43 vs. PRXL: 45.99 )
Ranked among companies with meaningful Shiller P/E only.
PRXL' s Shiller P/E Range Over the Past 10 Years
Min: 22.56  Med: 55.69 Max: 124
Current: 45.99
22.56
124
Current Ratio 1.63
PRXL's Current Ratio is ranked lower than
73% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.89 vs. PRXL: 1.63 )
Ranked among companies with meaningful Current Ratio only.
PRXL' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 1.64 Max: 3.36
Current: 1.63
1.21
3.36
Quick Ratio 1.63
PRXL's Quick Ratio is ranked lower than
65% of the 197 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. PRXL: 1.63 )
Ranked among companies with meaningful Quick Ratio only.
PRXL' s Quick Ratio Range Over the Past 10 Years
Min: 1.21  Med: 1.64 Max: 3.36
Current: 1.63
1.21
3.36
Days Sales Outstanding 84.70
PRXL's Days Sales Outstanding is ranked lower than
71% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.75 vs. PRXL: 84.70 )
Ranked among companies with meaningful Days Sales Outstanding only.
PRXL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.59  Med: 107.45 Max: 149.34
Current: 84.7
61.59
149.34
Days Payable 11.39
PRXL's Days Payable is ranked lower than
93% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.55 vs. PRXL: 11.39 )
Ranked among companies with meaningful Days Payable only.
PRXL' s Days Payable Range Over the Past 10 Years
Min: 7.12  Med: 13.37 Max: 17.88
Current: 11.39
7.12
17.88

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 52.21
PRXL's Price/Tangible Book is ranked lower than
98% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.40 vs. PRXL: 52.21 )
Ranked among companies with meaningful Price/Tangible Book only.
PRXL' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.13  Med: 5.32 Max: 77.59
Current: 52.21
1.13
77.59
Price/Projected FCF 1.93
PRXL's Price/Projected FCF is ranked higher than
56% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.11 vs. PRXL: 1.93 )
Ranked among companies with meaningful Price/Projected FCF only.
PRXL' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.44  Med: 2.31 Max: 8.33
Current: 1.93
1.44
8.33
Price/DCF (Earnings Based) 2.33
PRXL's Price/DCF (Earnings Based) is ranked lower than
56% of the 16 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.08 vs. PRXL: 2.33 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.37
PRXL's Price/Median PS Value is ranked lower than
76% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. PRXL: 1.37 )
Ranked among companies with meaningful Price/Median PS Value only.
PRXL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.35  Med: 0.91 Max: 4.1
Current: 1.37
0.35
4.1
Price/Peter Lynch Fair Value 1.09
PRXL's Price/Peter Lynch Fair Value is ranked higher than
85% of the 26 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.39 vs. PRXL: 1.09 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
PRXL' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.39  Med: 1.92 Max: 16.68
Current: 1.09
0.39
16.68
Price/Graham Number 7.59
PRXL's Price/Graham Number is ranked lower than
90% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.10 vs. PRXL: 7.59 )
Ranked among companies with meaningful Price/Graham Number only.
PRXL' s Price/Graham Number Range Over the Past 10 Years
Min: 0.87  Med: 2.90 Max: 9.75
Current: 7.59
0.87
9.75
Earnings Yield (Greenblatt) (%) 5.10
PRXL's Earnings Yield (Greenblatt) (%) is ranked higher than
77% of the 227 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.60 vs. PRXL: 5.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
PRXL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.4  Med: 5.70 Max: 16.9
Current: 5.1
0.4
16.9
Forward Rate of Return (Yacktman) (%) 26.20
PRXL's Forward Rate of Return (Yacktman) (%) is ranked higher than
83% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.32 vs. PRXL: 26.20 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
PRXL' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 3.8  Med: 17.30 Max: 33.6
Current: 26.2
3.8
33.6

More Statistics

Revenue (TTM) (Mil) $2,406
EPS (TTM) $ 2.68
Beta0.49
Short Percentage of Float8.33%
52-Week Range $56.00 - 76.17
Shares Outstanding (Mil)52.89

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Jun16 Jun17 Jun18
Revenue (Mil $) 2,092 2,215 2,318
EPS ($) 3.24 3.83 4.51
EPS w/o NRI ($) 3.24 3.83 4.51
EPS Growth Rate
(3Y to 5Y Estimate)
14.49%
Dividends Per Share ($)
» More Articles for NAS:PRXL

Headlines

Articles On GuruFocus.com
Parexcel: Great Growth but a Tough Business Aug 17 2011 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 12,920 Shares Mar 11 2011 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 1,500 Shares Mar 11 2011 
PAREXEL International Corp. Reports Operating Results (10-Q) Feb 09 2011 
PAREXEL International Corp. Reports Operating Results (10-Q) Nov 09 2010 
PAREXEL International Corp. Reports Operating Results (10-K/A) Sep 09 2010 
PAREXEL International Corp. Reports Operating Results (10-K) Aug 27 2010 
PAREXEL International Corp. Reports Operating Results (10-Q) May 07 2010 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 13,149 Shares Mar 12 2010 
PAREXEL International Corp. (PRXL) Senior VP & CFO James F Jr Winschel sells 15,600 Shares Mar 04 2010 

More From Other Websites
Companies Try New Ways to Attract Patients to Drug Trials Jul 18 2016
PAREXEL INTERNATIONAL CORP Files SEC form 8-K, Change in Directors or Principal Officers Jul 15 2016
PAREXEL International Announces Date of Fourth Quarter and Fiscal Year 2016 Earnings Release and... Jul 11 2016
PAREXEL International Corp. – Value Analysis (NASDAQ:PRXL) : July 5, 2016 Jul 05 2016
PAREXEL's (PRXL) Updated Long-term View Raises Hope Jul 05 2016
PAREXEL International Corp. breached its 50 day moving average in a Bullish Manner : PRXL-US : July... Jul 01 2016
[$$] Parexel Sees Restructuring Costs Further Denting Profit Jun 30 2016
PAREXEL International Outlines Growth Strategy and Updates Financial Guidance at Investor Day Jun 30 2016
Healthcare Opportunities in Light of Brexit-Driven Selloff Jun 28 2016
Coverage initiated on PAREXEL by Credit Suisse Jun 21 2016
PAREXEL Experts to Discuss Key Drug Development Insights at DIA 2016 Jun 20 2016
PAREXEL Invites Public to Listen to Live Webcast of Investor Day Presentations on June 30 Jun 15 2016
PAREXEL Announces Master Services Agreement with Pfizer Jun 10 2016
PAREXEL Named Company of the Year for the Pharmaceuticals Industry with a Gold Stevie from the... Jun 02 2016
PAREXEL International to Present at Goldman Sachs Global Healthcare Conference and Jefferies... May 24 2016
PAREXEL International to Present at UBS Healthcare Conference May 09 2016
PAREXEL INTERNATIONAL CORP Financials May 07 2016
PAREXEL INTERNATIONAL CORP Files SEC form 10-Q, Quarterly Report May 03 2016
ETF’s with exposure to PAREXEL International Corp. : May 2, 2016 May 02 2016
PAREXEL International Corp. :PRXL-US: Earnings Analysis: Q3, 2016 By the Numbers Apr 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)